We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China.
- Authors
Yu, Uet; Xu, Huanli; Chen, Senmin; Yi, Meng; Liu, Chao; Zhang, Xiaoling; Wang, Chunjing; Song, Jianming; Gan, Yungen; Wang, Jianyao; Wang, Yuanxiang; Zhang, Qing; Sun, Junjie; Xia, Bei; Zhang, Gongwei; Li, Changgang; Wen, Feiqiu; Liu, Sixi; Yuan, Xiuli
- Abstract
Objective: Recent therapeutic advances have greatly enhanced the survival rates of patients with neuroblastoma (NB). However, the outcomes of neuroblastoma patients in China, particularly those with high-risk (HR) NB, remain limited. Method: We retrospectively analyzed the clinical data and outcomes of NB patients who were treated at a tertiary pediatric cancer facility in China between January 2013 and October 2021. Results: A total of 117 NB patients were recruited. Patients with very low-risk (VLR), low-risk (LR), intermediate-risk (IR), and HR-NB patients made up 4%, 27%, 15%, and 54% of total patient population, respectively. Patients diagnosed between 2013 and 2018 were treated according to the protocol of Sun Yat-Sen University Cancer Center and those diagnosed between 2019 and 2021 were treated according to the COG ANBL0531 or ANBL0532 protocol with or without autologous stem cell transplantation (ASCT). The 5-year EFS and OS of all risk groups of patients were 67.29% and 77.90%, respectively. EFS and OS were significantly decreased in patients with higher risk classifications (EFS: VLR/LR vs IR vs HR: 97.22% vs 67.28% vs 51.83%; ***P =.001; OS: VLR/LR vs IR vs HR: 97.06% vs 94.12% vs 64.38%; *P =.046). In HR-NB patients treated according to the COG protocol between 2019 and 2021, the 3-year OS of patients who received tandem ASCT was significantly greater than those who did not receive ASCT (93.33% % vs 47.41%; *P =.046; log-rank test). EFS was not significantly different between patients with and without ASCT (72.16% vs 60.32%). Conclusion: Our findings show that patients with lower risk classification have a positive prognosis for survival. The prognosis of patients with HR-NB remains in need of improvement. ASCT may enhance OS in HR-NB patients; however, protocol adjustment may be necessary to increase EFS in these patients.
- Publication
Cancer Control: Journal of the Moffitt Cancer Center, 2023, p1
- ISSN
1073-2748
- Publication type
Article
- DOI
10.1177/10732748231187837